Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 24, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - July 24, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/24/14 - "Glp-1 and Methods for Treating Diabetes" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor Steiness, Eva, filed on February 10, 2014, was made available online on July 10, 2014, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application is assigned to Zealand Pharma A/s. See
7/24/14 - "Syringe with Co-Molded Hub and Cannula" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor LUNDQUIST, Jon Tyler, filed on March 7, 2014, was made available online on July 10, 2014, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application is assigned to West Pharmaceutical S
7/24/14 - Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
Acasti Pharma Inc., an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has been selected to give an oral presentation at the 19 th World Congress on H
7/24/14 - Achillion Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., July 24 Achillion Pharmaceuticals, New Haven, Connecticut, has been assigned a patent developed by four co-inventors for "macrocyclic peptides as inhibitors of viral replication." The co-inventors are Avinash Phadke, Branford, Connecticut, Xiangzhu Wang, Madison, Connecticut, Suoming Zhang, Palo Alto, California, and Atul Agarwal
7/24/14 - Aerie Pharmaceuticals, Inc. Receives Health Canada No Objection Letter to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada
BEDMINSTER, N.J.& RESEARCH TRIANGLE PARK, N.C.& NEWPORT BEACH, Calif. Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it has received a No Objection Letter from Health Canada to conduct a Phase 3 registrati
7/24/14 - Alexion Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., July 24 Alexion Pharmaceuticals, Cheshire, Connecticut, has been assigned a patent developed by three co-inventors for "rationally designed antibodies." The co-inventors are Katherine S. Bowdish, Del Mar, California, Mark Renshaw, San Diego, and Shana Frederickson, Solana Beach, California. Written by Vessie Ann Abalos.
7/24/14 - Allergy Therapeutics Full Year Revenues To Beat Market Expectations
LONDON- Allergy Therapeutics PLC said Thursday that it will see revenues before milestones and rebates ahead of the previous year, and above market expectations for the year to end-June. The pharmaceutical company said that it will post revenues of GBP45.7 million, up from GBP39.9 million in the previous year. Shares in Allergy Therapeutics were tr
7/24/14 - Back to the dark ages of medicine ; The government's top doctor says antibitoic resistance is as great a threat as terrorism. Lisa Salmon reports on... [Newcastle Journal (England)]
Back to the dark ages of medicine; The government's top doctor says antibitoic resistance is as great a threat as terrorism. Lisa Salmon reports on the rise of superbugs. It's estimated that drug- resistant strains of bacteria are responsible for 5,000 deaths a year in the UK and 25,000 it's estimated that drug-resistant strains of bacteria are res
7/24/14 - Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks
The first part of the session on "Best Practices for Optimizing Dose Escalation in First in Human Studies" will cover comprehensive clinical support in early phase studies to make better go/no-go decisions. With increasing R&D costs and declining industry success in getting products to market, pharmaceutical companies need to maximize the knowledge
7/24/14 - BioAlliance Pharma Partner Innocutis Launches Sitavig in U.S. [Manufacturing Close - Up]
BioAlliance Pharma noted that herpes labialis is an extremely widespread condition. "The U.S. launch of Sitavig, a drug from the R&D of BioAlliance Pharma, confirms once more our know-how in the development and registration of products in the U.S. We are very confident in Innocutis' sales team commitment and know-how to successfully implement the
7/24/14 - BioAlliance Pharma: Approval of Onxeo's admission to secondary listing and trading on NASDAQ OMX Copenhagen
In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA, an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S, today announce that NASDAQ OMX Copenhagen has approved Onxeo s admission to secondary trading and official listing on NASDA
7/24/14 - Biosimilar Retacrit(TM) Effective in Chemotherapy-Induced Anemia - New Publication in BMC Cancer of ORHEO Study Results
LEAMINGTON SPA, England, July 24, 2014/ PRNewswire/ Hospira, the world's leading provider of injectable drugs and infusion technologies, announced today that the results from the ORHEO study have been published in BMC Cancer, and show that the company's European biosimilar epoetin, Retacrit (TM) was effective and well tolerated in the management
7/24/14 - Boston Scientific Garners FDA Approval for REBEL Platinum Chromium Coronary Stent System [Professional Services Close - Up]
Boston Scientific has received FDA approval for the REBEL Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease. The REBEL Stent System expands the Boston Scientific family of stents featuring its proprietary platinum chromium alloy and a customized stent architecture.
7/24/14 - BrainStorm's Clinical Trial is Fast-Tracked to Phase IIa; CEL-SCI Expands Its Phase III Head and Neck Cancer Trial
The trial, which will evaluate the safety and preliminary efficacy of BrainStorm s NurOwn stem cell therapy candidate, will be launched immediately at the Hadassah Medical Center in Jerusalem. The Ministry of Health approved acceleration to a Phase IIa trial based on evaluation of only 12 of the initial cohort of 24 patients in the company s
7/24/14 - BRISTOL MYERS SQUIBB CO - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
In July 2014, the Company announced that the Japanese Ministry of Health, Labor and Welfare approved Daklinza and Sunvepra for Japan's first all-oral, interferon- and ribavirin-free treatment regimen for patients with genotype 1 chronic hepatitis C virus infection, particularly those with compensated cirrhosis. In July 2014, the Company and Ono...
7/24/14 - Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer
Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer. The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Celsion previously reported combined clinic
7/24/14 - Clementia Pharmaceuticals Receives U.S. Orphan Drug Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva
Clementia Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted the Company's lead product candidate, palovarotene, Orphan Drug Designation for the treatment of Fibrodysplasia Ossificans Progressiva. Jeff Packman, Chief Development Officer of Clementia, stated, "Following the recent initiation of our Phase 2.
7/24/14 - Clinigen Confident For "Another Strong Year Ahead" As Revenues Rise
LONDON- Pharmaceutical company Clinigen Group PLC said Thursday it saw revenues rise by over 7% on a constant currency basis in the year to end-June, and expressed confidence for "another strong year ahead". The company said its revenues at actual currencies were not less than GBP126 million for the year. Clinigen said its closing cash position was
7/24/14 - CorMatrix Receives FDA Approval to Market ECM for Vascular Repair [Health & Beauty Close - Up]
CorMatrix Cardiovascular reported that it has received U.S. Food and Drug Administration clearance to market the CorMatrix ECM for Vascular Repair. Richard F. Neville, Professor of Surgery, Chief, Division of Vascular Surgery at George Washington University said, "CorMatrix ECM for Vascular Repair is an innovative scaffold permitting the patient's
7/24/14 - CORRECTION: Approval of Onxeo's admission to secondary listing and trading on NASDAQ OMX Copenhagen
In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA, an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S, today announce that NASDAQ OMX Copenhagen has approved Onxeo s admission to secondary trading and official listing on NASDA
7/24/14 - Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery
Cypher Genomics, Inc., the genome informatics company, announced today a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials. "Cypher Genomics' biomarker discovery service is a perfect complement to Illumina's whole genome sequen
7/24/14 - DRUG FIRMS IN DOCK FOR FLEECING PATIENTS [Mail Today (India)]
The pricing anomaly has been caught by National Pharmaceutical Pricing Authority which has filed 22 cases this year alone, sending out demand notices that add up to ` 221.78 crore. Only ` 54.23 crore of this has been recovered from pharmaceutical companies so far. It is equally important that the government gets success in price control in the best
7/24/14 - Eagle Pharmaceuticals drug OK'd [The Record (Hackensack, N.J.) :: ]
July 24 Woodcliff Lake- based Eagle Pharmaceuticals Inc. said Wednesday that the Food and Drug Administration has approved its use of the drug Ryanodex, which is used for the treatment of malignant hyperthermia, making the drug the first product to be solely marketed by the company. Shares of Eagle climbed as much as 4.7 percent to $13.68 Wednesd
7/24/14 - Endo Pharmaceuticals Solutions Assigned Patent
ALEXANDRIA, Va., July 24 Endo Pharmaceuticals Solutions, Malvern, Pennsylvania, has been assigned a patent developed by Petr Kuzma, Princeton, New Jersey, and Harry Quandt, Bensalem, Pennsylvania, for "long term drug delivery devices with polyurethane-based polymers and their manufacture." The patent application was filed on May 13, 2013. Written
7/24/14 - Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension
Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced dosing of the first patient in its Phase 2...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415